Myelin formation

Myelin formation, also known as myelination, is a complex multi-stage biological process in which specialized glial cells—oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS)—wrap neuronal axons with an insulating, lipid-rich sheath [1, 19]. This sheath is vital for the rapid and efficient transmission of electrical impulses via saltatory conduction and provides essential trophic and metabolic support to maintain axonal health [6, 17]. Pathological demyelination, most notably seen in multiple sclerosis (MS), disrupts neural signaling and leaves axons susceptible to degeneration, leading to progressive clinical disability [4, 5, 11]. While myelin formation is a physiological process rather than a single molecular target, it is the primary goal of remyelination therapies that aim to stimulate endogenous repair [2, 10]. Modern drug discovery efforts focus on promoting the differentiation of oligodendrocyte progenitor cells (OPCs) and overcoming inhibitory environmental cues through various molecular targets such as LINGO-1, muscarinic receptors, and retinoid X receptors [5, 10, 18]. Successful therapeutic induction of myelin formation holds the potential to restore function and slow neurodegeneration in a wide range of neurological disorders [7, 15].

Other names

MyelinationRemyelinationMyelinogenesisMyelin repair

The mechanism involves the pharmacological stimulation of oligodendrocyte progenitor cell (OPC) recruitment, proliferation, and subsequent differentiation into mature, myelin-producing oligodendrocytes. This is achieved by antagonizing inhibitory signaling pathways (e.g., LINGO-1 blockade), activating pro-myelinating nuclear receptors (e.g., RXR-gamma), or modulating G protein-coupled receptors (e.g., muscarinic M1, histamine H3) to overcome the maturation block in demyelinated lesions [5, 10, 18].